CRVSCorvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc. (CRVS) sells soquelitinib, an investigational IL-31RA inhibitor for atopic dermatitis and asthma. The next catalyst is Jan 31, 2027 — Phase 2 Soquelitinib Topline Data (Atopic Dermatitis), which will test the drug’s efficacy in a key indication. The data will reveal whether the asset can move beyond Phase 1 positive signals and attract broader investor interest.
- CRVS has a narrow product pipeline centered on soquelitinib, with limited near-term revenue.
- The company is heavily leveraged, with $61.20M in shareholders’ equity and $74.85M in negative free cash flow over the last 12 months.
- The stock has struggled with dilution and financing uncertainty, with recent earnings misses amplifying volatility.
The Read
CRVS’s stock fell about 11% after dilution fears post-$201M offering despite strong soquelitinib data, then dropped nearly 27% on Q4 earnings due to unclear financing but rebounded about 8% after positive Q1 soquelitinib updates.
The schedule
- Tue9Feb
This earnings report will test the company’s ability to sustain momentum from the prior quarter, with a focus on revenue growth and clinical trial progress, particularly for Soquelitinib. The prior print showed a strong bull move after a bearish period.
- Thu6May
The earnings report will test whether CRVS can maintain its recent bull run by delivering strong guidance and revenue growth, following a prior earnings print that saw a sharp rebound after a bearish period.
- Thu5Aug
This earnings report will test the company’s ability to sustain momentum from the prior quarter, with a focus on revenue growth and clinical trial progress, particularly for Soquelitinib. The prior print showed a strong bull move after a bearish period.
- Thu4Nov
Past
- Fri16Oct
Actual outcome: Bull · $10.25 at outcome
CRVS stock surged 10% on the event date, hitting the 50-DMA for the first time, and closed at $10.35 by the outcome date, surpassing the bull target of $10.54. The rally was driven by positive technical momentum and the stock's ability to sustain the breakout, indicating strong investor confidence in the company's long-term growth potential despite earlier liquidity concerns.
The surge tests whether the stock can sustain momentum from a technical breakout, contrasting with the last rally that stalled on liquidity concerns.
- Tue8Sep
Actual outcome: Bull · $13.46 at outcome
CRVS reported EPS of -0.56, matching the estimate, but provided updated cash runway guidance indicating extended financial flexibility. The stock rose as the cash runway update signaled improved liquidity and strategic positioning, outweighing the neutral earnings beat. The positive move was driven by the updated guidance, not the earnings result itself.
The earnings test focuses on cash runway and guidance reset, differing from the last print where the focus was on revenue mix and margin commentary.
- Tue9Jun
Actual outcome: Bull · $11.60 at outcome
Corvus reported in-line earnings with an EPS of -$0.15, meeting estimates exactly and demonstrating stable cash burn. Concurrently, the company announced a $5 million investment in Angel Pharmaceuticals to advance clinical trials of soquelitinib in China for atopic dermatitis and asthma. This strategic expansion of their key asset's global development pipeline provided positive momentum, driving an initial 3.8% gain that continued to rally well past the $13.00 bull target in the following weeks.
The Phase 2 top-line data for Soquelitinib in Atopic Dermatitis will test the drug's potential to drive product mix and revenue growth, with a focus on clinical outcomes and trial progress.
- Tue9Jun
Actual outcome: Bull · $11.60 at outcome
Corvus reported in-line earnings with an EPS of -$0.15, meeting estimates exactly and demonstrating stable cash burn. Concurrently, the company announced a $5 million investment in Angel Pharmaceuticals to advance clinical trials of soquelitinib in China for atopic dermatitis and asthma. This strategic expansion of their key asset's global development pipeline provided positive momentum, driving an initial 3.8% gain that continued to rally well past the $13.00 bull target in the following weeks.
Q2 2026 results and pipeline update will focus on cash burn, runway after the early-2026 raise, and new efficacy and safety signals from soquelitinib, driving a reassessment of Corvus’ valuation around $11.17.
- Thu7May
Actual outcome: Bull · $15.81 at outcome
Corvus Pharmaceuticals met Q1 2026 EPS estimates at -$0.18 and provided a highly constructive clinical update on its soquelitinib program. The stock rallied 8.4% as investors were encouraged by positive Phase 1 cohort 4 data in atopic dermatitis, the initiation of a Phase 2 trial, and the announcement of upcoming biomarker data supporting the drug's potential to produce drug-free remissions.
Q1 2026 earnings call focused on cash runway after the January equity raise and enrollment progress in the Phase 3 PTCL and Phase 2 atopic dermatitis soquelitinib programs. At a base price of $14.69, a constructive update on trial timelines and burn could lift the stock toward $17.00, while slower enrollment, higher-than-expected cash burn, or hints of future financing needs could push it down toward $17.00.
- Thu12Mar
Actual outcome: Mixed · $15.72 at outcome
Corvus Pharmaceuticals reported Q4 2025 EPS of -$0.18, meeting estimates, and announced positive Phase 1 data for soquelitinib in atopic dermatitis. However, the earnings update was poorly received, as the company failed to provide the necessary confirmation of a financing deal to extend its critically low cash runway. This lack of financial clarity overshadowed the clinical data, causing the stock to sell off following the report and continue trending downward toward the bear floor.
Focus on cash runway, which was critically low in Q3 2025. Positive re-rate requires confirmation of a financing deal to extend runway beyond Q4 2026. Failure to confirm financing will lead to severe asymmetric downside.
- Thu29Jan
Actual outcome: Bear · $18.66 at outcome
CRVS successfully closed its upsized $201 million public offering (priced at $22.15) following a massive rally driven by positive soquelitinib data. However, the expected consolidation near the offering price failed to materialize. Instead, the stock experienced significant short-term selling pressure related to the dilution overhang, causing the price to fall 10.9% and settle near the bear floor ($18.66 vs. $18.50), indicating the market prioritized dilution over the de-risked balance sheet.
Short-term price action following the recent upsized $175M public offering (priced at $22.15). The dilution overhang will be countered by the de-risked balance sheet and cash runway being secured. Consolidation is expected near the offering price.